These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29911403)

  • 61. Semaglutide, Ertugliflozin, and Deflazacort.
    Hussar DA; Bailey KJ
    J Am Pharm Assoc (2003); 2018; 58(3):321-325. PubMed ID: 29739505
    [No Abstract]   [Full Text] [Related]  

  • 62. How do the top 12 pharmaceutical companies operate safety pharmacology?
    Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CROs and CNS research: challenges and trends.
    Olugemo K
    Drug Discov Today; 2018 Jun; 23(6):1167-1168. PubMed ID: 29378251
    [No Abstract]   [Full Text] [Related]  

  • 64. Contract research organizations (CROs) may be the next trend in clinical trials liability.
    Valdes S; McGuire P
    J Biolaw Bus; 2004; 7(3):11-5. PubMed ID: 15460602
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
    Woo TE; Kuzel P
    Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Russ H; Busta S; Jost B; Bethke TD
    Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An Examination of eClinical Technology Usage and CDISC Standards Adoption.
    Lamberti MJ; Kush R; Kubick W; Henderson C; Hinkson B; Kamenju P; Getz KA
    Ther Innov Regul Sci; 2015 Nov; 49(6):869-876. PubMed ID: 30222377
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Setting the RECORD Straight.
    Nissen SE
    JAMA; 2010 Mar; 303(12):1194-5. PubMed ID: 20332408
    [No Abstract]   [Full Text] [Related]  

  • 69. Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action.
    Hirsch IB; Martinez J; Dorsey ER; Finken G; Fleming A; Gropp C; Home P; Kaufer DI; Papapetropoulos S
    Clin Ther; 2017 May; 39(5):1064-1076. PubMed ID: 28413148
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outsourcing lead optimization: constant change is here to stay.
    Clark DE
    Drug Discov Today; 2007 Jan; 12(1-2):62-70. PubMed ID: 17198974
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comparative analysis of quality management standards for contract research organisations in clinical trials.
    Murray E; McAdam R
    Int J Health Care Qual Assur; 2007; 20(1):16-33. PubMed ID: 18240505
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus.
    Jiang M; Steyger PS
    Expert Opin Ther Pat; 2015; 25(11):1349-52. PubMed ID: 26291462
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?
    Chan JK; Ueda SM; Sugiyama VE; Stave CD; Shin JY; Monk BJ; Sikic BI; Osann K; Kapp DS
    J Clin Oncol; 2008 Mar; 26(9):1511-8. PubMed ID: 18285603
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Navigating the Murky Waters of Conflict of Interest: Searching for the Middle Path.
    Zonia SC
    J Empir Res Hum Res Ethics; 2016 Feb; 11(1):67-71. PubMed ID: 27106892
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bioanalytical outsourcing models in pharmaceutical companies.
    Zimmer D
    Bioanalysis; 2017 Aug; 9(15):1145-1148. PubMed ID: 28763250
    [No Abstract]   [Full Text] [Related]  

  • 79. Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience.
    Soran A; Nesbitt L; Mamounas EP; Lembersky B; Bryant J; Anderson S; Brown A; Passarello M
    Clin Trials; 2006; 3(5):478-85. PubMed ID: 17060221
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New, strategic outsourcing models to meet changing clinical development needs.
    Jones J; Minor M
    Perspect Clin Res; 2010 Apr; 1(2):76-9. PubMed ID: 21829788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.